Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma

Drugs

Volumn 55, Issue 2, 1998, Pages 303-322

  Bartow, Rebecca A ^a   Brogden, Rex N ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; CORTICOSTEROID; FENOTEROL; FORMOTEROL; SALBUTAMOL; SALMETEROL; TERBUTALINE;

ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EXERCISE; HEADACHE; HEART PALPITATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; META ANALYSIS; MUSCLE CRAMP; PRACTICE GUIDELINE; REVIEW; SYMPTOM; TREMOR;

EID: 0031939664     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855020-00016     Document Type: Review

References (89)

1. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991 Jul; 42: 115-37
2. Maesen FPV, Costongs R, Smeets SJ. Formoterol as dry powder inhalation: a dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992 May; 101: 1376-81
3. Ringdal N, Derom E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler (Rm) in mild to moderate asthma [abstract]. Eur Respir J 1945 Sep; 8 Suppl. 19: 68
4. Vandenberg BTJ, Smeets JJ, Vanboxtel CJ, et al. Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients. Fundam Clin Pharmacol 1995; 9 (6): 593-603
5. Maesen FPV, Smeets SJ, Costongs MAL. Onset of action of eformoterol by dry powder inhaler: objective and subjective measures. Br J Clin Pract 1995 Nov-Dec; 49: 294-6
6. Ullman A, Löfdahl C-G, Melander B, et al. Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study. Allergy 1996 Oct; 51: 745-8
7. Wallin A, Sandström T, Rosenhall L. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993 Jun; 48: 611-4
8. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 1992 Jan; 47: 30-3
9. Lebecque P, Vliers S, Desaintmoulin T, et al. Response to a single dose of inhaled formoterol in asthmatic children - a double-blind randomized controlled study [in French]. Rev Mal Respir 1994; 11 (1): 47-50
10. Wegener T, Hedenström H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992 Aug; 102: 535-8
11. Wong BJO, Kamada DH, Kolendowicz R, et al. Inhibition of allergen-induced airway and inflammatory responses by formoterol and beclomethasone [abstract]. J Allergy Clin Immunol 1992 Jan; 89: 176
12. Corvaja E, Giacobbe G, Girbino G. Bronchial response to salbutamol versus formoterol assessed by respiratory impedance [abstract]. Allergy 1996; 51 Suppl. 30: 79
13. Lötvall J, Lazer L, Persson G, et al. Formoterol Turbuhaler® has a faster onset of action but a similar duration of effect compared with salmeterol Diskhaler® at equipotent doses [abstract no. 62]. Am J Respir Crit Care Med 1996; 153 (4 Pt 2)
14. van Noord JA, Smeets JJ, Raaijmakers JAM. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996 Aug; 9: 1684-8
15. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary diseases. Pulmon Pharmacol 1994 Apr; 7: 103-7
16. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995 May; 89: 357-62
17. Ramsdale EH, Otis J, Kline PA, et al. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta2-agonist formoterol. Am Rev Respir Dis 1991 May; 143: 998-1001
18. Beach JR, Bromly CL, Avery AJ, et al. Speeds of action of formoterol and salbutamol after methacholine induced bronchoconstriction [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 96
19. Sovijarvi ARA, Reinikainen K, Freudenthal Y, et al. Preventive effects of inhaled formoterol and salbutamol on histamine-induced bronchoconstriction - a placebo-controlled study. Respiration 1992 Sep-Oct; 59: 279-82
20. Malo J-L, Cartier A, Trudeau C, et al. Formoterol, a new inhaled beta-2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Am Rev Respir Dis 1990; 142: 1147-52
21. Palmqvist M, Balder B, Löwhagen O, et al. Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beut2-agonist. J Allergy Clin Immunol 1992 Apr; 89: 844-9
22. Wong BJ, Dolovich J, Ramsdale EH, et al. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. Am Rev Respir Dis 1992 Nov; 146 (Pt 1): 1156-60
23. Rabe KF, Jörres R, Nowak D. Comparison of the effects of salmeterol and tormoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993 Jun; 147 (Pt 1): 1436-41
24. Zellweger JP, Pfenninger M, Ruff P, et al. 24-hour protective effect of salmeterol xinafoate (50 meg) versus formoterol (24 meg) against methacholine-induced bronchoconstriction in mild to moderate asthmatic patients: a randomized, double-blind, cross-over, single-dose trial [abstract]. Eur Respir J 1994; 7 Suppl. 18: 422
25. Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993 Feb; 6: 204-10
26. Burgess C, Ayson M, Rajasingham S, et al. The cardiovascular and metabolic effects of increasing doses of formoterol in patients with asthma [abstract]. Eur Respir J 1994; 7 Suppl. 18: 204
27. Nishikawa M, Mak JCW, Barnes PJ. Selective beta-2-agonists, salbutamol, salmeterol and formoterol down-regulate beta-2-adrenoceptor [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2): 483
28. Grove A, Lipworth BJ. Evaluation of the beta-2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax 1996 Jan; 51: 54-8
29. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994 Jul; 97: 29-37
30. Newnham DM, Grove A, McDevitt DG. Subsensitivity of bronchodilator and systemic beta-2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995 May; 50: 497-504
31. Maesen FPV, Costongs R, Smeets JJ. The effects of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 1991 Jun; 99: 1367-73
32. McCrea KE, Hill SJ. Salmeterol, but not formoterol produces persistent cAMP accumulation in the B50 neuronal cell line [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2): 91
33. Lindberg S, Khan R, Runer T. The effects of formoterol, a long-acting beta-2-adrenoceptor agonist, on mucociliary activity. Eur J Pharmacol 1995 Oct 24; 285: 275-80
34. Melloni B, Germouty J. The influence on muco-ciliary function of formoterol - a new beta-agonist [in French]. Rev Mal Respir 1992; 9 (5): 503-7
35. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 1994 Mar; 7: 569-78
36. Waldeck B. Some pharmacodynamic aspects on long-acting beta-adrenoceptor agonists. Gen Pharmacol 1996 Jun; 27: 575-80
37. Butter JJ, van den Berg BTJ, Portier EJG, et al. Determination by HPLC with electrochemical detection of formoterol enantiomers in urine of healthy human subjects after single dose racemate inhalations [abstract]. Pharm World Sci 1995 May 26; 17 Suppl. D: 6
38. Braat MCP, Portier EJG, van den Berg BTJ, et al. Formoterol detection and pharmacokinetics in human subjects after an oral dose of 168 micrograms [abstract]. Am Rev Respir Dis 1992 Apr; 145: A60
39. Derks MGM, van den Berg BTJ, van der Zee JS, et al, Pharmacokinetics/pharmacodynamics of inhaled formoterol [abstract]. Neth J Med 1995 May; 46: A54
40. Grossman J, Busse W, Kreitzer S, et al. Double-blind, crossover trial of formoterol aerosol in patients with asthma [abstract no. P35]. In: 1996 Annual Meeting of the American College of Allergy, Asthma and Immunology 1996: 33
41. Kemp JP, Chervinsky P, Nelson H, et al. A randomised, double-blind, placebo-controlled, dose-response study with formoterol Turbuhaler® [abstract no. 1343]. J Allergy Clin Immunol 1997; 99 (Pt 2): S329
42. Häicki MA, Ritter AM, Medici TC. Long-acting beta-2-agonists: regular daily use of formoterol over five years [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 259
43. Shima K, Takenaka S. The clinical evaluation of formoterol (BD 40A) in bronchial asthma with long term administration and in chronic obstructive pulmonary disease with short term administration. Yakuri to Chiryo 1983; 11: 3935-42
44. Clauzel AM, Rifaï N, Bony C, et al. Safety of formoterol administered over 20 months in 68 severe asthmatics [abstract]. J Allergy Clin Immunol 1992 Jan; 89: 176
45. Kesten S, Chapman KR, Broder I, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992 Nov; 69: 415-20
46. Steffensen I, Faurschou P, Riska H, et al. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease: a 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy 1995 Aug; 50: 657-63
47. Maesen FPV. Longlasting treatment of stable moderately severe asthma patients with formoterol alone does not lead to desensitization [abstract]. Eur Respir J 1994; 7 Suppl. 18: 110
48. Maesen BLP, Smeets SJ, Costongs R, et al. Long-term effects of the beta-2-adrenoreceptor agonist formoterol for two years on lung function of stable asthmatic patients [abstract]. Chest 1993 Mar; 103 Suppl.: 286
49. de Blic J, Kuusela AL. Formoterol dry powder capsules for inhalation in children with asthma treated over one year [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 14
50. Hock W, Eisele I, Hoyer H, et al. Long term effects of formoterol in patients with asthma receiving regular steroid therapy [abstract]. Eur Respir J 1992 Aug; 5 Suppl. 15: 208
51. Nielsen KG, Skov M, Klug B, et al. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer®. Eur Respir J 1997; 10: 2105-9
52. Angus RM, Thomson NC, Uk ESG, et al. Comparison of the efficacy and tolerability of eformoterol and salbutamol dry powder capsules for inhalation in elderly asthmatic patients [abstract]. Thorax 1995 Apr; 50: 469P
53. Arvidsson P, Larsson S, Löfdahl C-G, et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991 Nov; 4: 1168-73
54. Kesten S, Chapman KR, Broder I, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991 Sep; 144: 622-5
55. Maesen FPV, Dutch FPCG. Formoterol versus salbutamol. The Dutch 15 months study [abstract]. Chest 1995 Sep; 108 Suppl.: 209
56. Midgren B, Melander B, Persson G. Formoterol, a new long-acting beta2 agonist, inhaled twice daily, in stable asthmatic subjects. Chest 1992 Apr; 101: 1019-22
57. Sprogoe-Jakobsen U, Viktrup L, Davidsen O, et al. Bronchial asthma treated with long-acting beta 2 agonist: comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily [in Danish]. Ugeskr Laeger 1492 Nov 16; 154: 3325-8
58. Stalenheim G, Wegener T, Grettve L, et al. Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease. Respiration 1994 Nov-Dec; 61: 305-9
59. Becker AB, Lukowski JL, Simons FER, et al. Formoterol modifies chronic airway hyperresponsiveness in children with asthma [abstract]. J Allergy Clin Immunol 1991 Jan; 87 (Pt 2): 308
60. Tsoy AN, Cheltzov VV, Zaseyeva OV, et al. Formoterol and terbutaline aerosols in nocturnal asthma. Eur Respir J 1990 Sep; 3 Suppl. 10: 418S
61. Ekstrom T, Ringdal N, Tukiainen P. Formoterol Turbuhaler (Rm) 12 micrograms b.i.d. improves lung function in asthmatic patients compared with terbutaline and placebo [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 157
62. Brusasco V, Ringdal N, Ekström T, et al. Eftect of formoterol 6 micrograms b.i.d. via Turbuhaler® for 3 months in asthma: comparison with terbutaline and placebo [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 158
63. Pauwels RA, Löfdahl C-G, Postma PS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997 Nov 13; 337 (20): 1405-11
64. Van der Molen T, Postma DS, Turner MO, et al. Effects of the long acting β-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997 Jun; 52: 535-9
65. Bouros D. Formoterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in adult asthmatic patients: a multicenter trial [abstract no. 0150]. Eur Respir J 1997 Sep; 10 Suppl. 25: 1s
66. 2-agonists: formoterol and salmeterol [abstract no. O158]. Eur Respir J 1997 Sep; 10 Suppl. 25: 3s
67. Boner AL, Spezia F, Piovesan P. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 1): 935-9
68. Daugbjerg P, Nielsen KG, Skov M, et al. Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercised-induced asthma in children. Acta Paediatr 1996 Jun; 85: 684-7
69. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992 Jun; 89: 1176-82
70. Patessio A, Podda A, Carone M. Protective effect and duration of action of formoterol acrosol on exercise-induced asthma. Eur Respir J 1991 Mar; 4: 296-300
71. Guerin JC, Germain N, Febvre N, et al. Protective effect of formoterol on exercise-induced bronchoconstriction 10 hours after inhalation. Eur Respir J 1993 Sep; 6 Suppl. 17: 201S
72. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication: clinical implications of differences in effectiveness. Clin Immunother 1996 Oct; 6: 273-99
73. 2-agonists [abstract no. P1641]. Eur Respir J 1997 Sep; 10 Suppl. 25: 258s
74. Schreurs AJ, Sinninghe Damsté HE, de Graaff CS, et al. A dose response study with formoterol Turbuhaler® as maintenance therapy in asthmatic patients. Eur Respir J 1996 Aug; 9: 1678-83
75. Maesen FPV, Nakratzas G, Bantje TA. Formoterol suspension aerosol. Comparison with formoterol solution aerosol for 12 weeks in asthmatic patients. Chest 1992 Nov; 102: 1544-9
76. van der Molen T, Turner MO, Postma DS, et al. An international multi-centre randomised controlled trial of formoterol in asthmatics requiring inhaled corticosteroid. Eur Respir J 1995; 8 Suppl. 19: 2s
77. Bauer K, Sertl K, Kaik B. Effect of solution and suspension type aerosol of formoterol on tremor response and airways in patients with asthma. J Allergy Clin Immunol 1995 Oct; 96: 495-501
78. Eformoterol - a second long acting beta-2 agonist [editorial]. Pharm J 1996 Jan 13; 256: 52
79. Svedmyr N, Löfdahl C-G. The use of beta2-adrenoceptor agonists in the treatment of bronchial asthma. Pharmacol Toxicol 1996 Jan; 78: 3-11
80. Tilles SA, Nelson HS. Long-acting inhaled beta agonists. J Asthma 1995; 32 (6): 397-404
81. Barnes PJ, Barnett AH, Brewis RAL, et al. Guidelines for the management of asthma: a summary. BMJ 1993 Mar 20; 306: 776-82
82. British Guidelines on Asthma Management. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997 Feb; 52 Suppl. 1: 1-20
83. National Heart Lung Blood Institute. Diagnosis and classification. In. Global initiative for asthma: global strategy for asthma management and prevention: NHLBI/WHO Workshop Report [Monograph online]. [Bethesda, MD]: National Heart Lung and Blood Institute;World Health Organization, 1995, 1997
84. North of EAGDG. North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of asthma in adults. BMJ 1996 Mar 23; 312: 762-6
85. Joint Task Force on Practice Parameters. Practice parameters for the diagnosis and treatment of asthma. J Allergy Clin Immunol 1995 Nov; 96 (Pt 2): 707-870
86. Ernst P, Fitzgerald JM, Spier S. Canadian Asthma Consensus Conference summary of recommendations. Can Resp J 1996; 3: 89-100
87. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994 Jul 23; 344: 219-24
88. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-8
89. Jack D. Drug treatment of bronchial asthma 1948-1995 - years of change. Int Pharm J 1996 Mar-Apr; 10: 50-2